The short version
Only one company currently supplies this market — there is no backup if it stumbles.
Market view
bimekizumab · Liquid
1 marketed package NDCs · 1 active manufacturer
Most dispensed: 160 mg/mL · Injection, Solution · #1 syringe, glass/carton / 1 ml in 1 syringe, glass · 160 mg/mL · Injection, Solution · #2 syringe, glass/carton / 1 ml in 1 syringe, glass · 320 mg/2mL · Injection, Solution · #1 syringe, glass/carton / 2 ml in 1 syringe, glass
What changed in the last 90 days
Every detected change for bimekizumab, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
- bimekizumabAug 26, 2026Mfr exitedUCB Pharma S.A. · bimekizumab
- BimzelxAug 19, 2026Price downNADAC $8021.619 → $8016.03643 per unit (-0.07%)
- BimzelxAug 19, 2026Price upNADAC $8017.368 → $8035.07333 per unit (+0.22%)
- BimzelxJul 22, 2026Price downNADAC $8023.83667 → $8021.619 per unit (-0.03%)
- BimzelxJul 22, 2026Price downNADAC $8046.42677 → $8017.368 per unit (-0.36%)
Common questions
- Is Bimekizumab in shortage right now?
- No. FDA does not currently list Bimekizumab in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Bimekizumab?
- 3 companies have marketed Bimekizumab in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
- What does Bimekizumab cost?
- The typical pharmacy pays about $8,025.55 per mL, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.